RGX-202 is an oral small molecule inhibitor of SLC6A8 that induces apoptosis (cell death) of colorectal cancer cells.
RGX-104 is an oral small molecule activator of LXR/APOE that inhibits the growth of tumor blood vessels (angiogenesis) and activates tumor myeloid cells to enhance the immune response against tumors.
Science underlying Inspirna’s technology and pipeline has been published in leading scientific journals
Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer￼
Favorable efficacy and safety support further development of RGX-202-01 in advanced or metastatic second-line colorectal cancer NEW YORK--(BUSINESS WIRE)--Inspirna, Inc.,
Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
ORR of 50% and median PFS of 11.8 months in patients with KRAS mutant advanced colorectal cancer (CRC) treated
Inspirna Announces Phase 1b RGX-202 Clinical Trial Data Selected for Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022 10:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small